This latter finding supports the potential use of HDAC8 activators as therapeutic tools to attenuate the progression of the neurodevelopmental impairments and related deformities in CdLS patients diagnosed with HDAC8 mutation. The gene discussed is HDAC8; the disease is Cornelia de Lange syndrome.